Richard Daniell sold $3.0M of TEVA
EVP, Europe Commercial at TEVA PHARMACEUTICAL INDUSTRIES LTD. 91,345 shares at an average of $32.66, traded Mar 4, 2026, filed Mar 6, 2026.
Score components
- +15RoleOfficer
- +25Trade size$3.0M at market
- +20Share of holdings soldSold 58% of holdings
- +15Cluster9 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -3.1%, 3m +10.1%, 6m +17.1%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-096584, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 4, 2026 | MOption exercise Ordinary Shares10b5-1 | +33,512 | - | - | 156,639 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Ordinary Shares10b5-1 | -33,512 | $32.46 | $1.1M | 123,127 | Mar 6, 2026 |
| Mar 4, 2026 | MOption exercise Ordinary Shares10b5-1 | +20,461 | - | - | 143,588 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Ordinary Shares10b5-1 | -20,461 | $32.46 | $664k | 123,127 | Mar 6, 2026 |
| Mar 4, 2026 | SOpen-market sale Ordinary Shares10b5-1 | -37,372 | $32.95 | $1.2M | 85,755 | Mar 6, 2026 |
| Mar 4, 2026 | MOption exercise Restricted Share Unitsderivative10b5-1 | -33,512 | $0.00 | $0 | 0 | Mar 6, 2026 |
| Mar 4, 2026 | MOption exercise Restricted Share Unitsderivative10b5-1 | -20,461 | $0.00 | $0 | 40,923 | Mar 6, 2026 |
| Mar 4, 2026 | AGrant or award Restricted Share Unitsderivative10b5-1 | +33,424 | $0.00 | $0 | 33,424 | Mar 6, 2026 |
Related signals
Other insiders at TEVA PHARMACEUTICAL INDUSTRIES LTD and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 68Notable | TEVA PHARMACEUTICAL INDUSTRIES LTD | Roberto Mignone director | $14M 367,600 shares | -100% | |
| 32Weak | TEVA PHARMACEUTICAL INDUSTRIES LTD | Brian Savage Interim Chief Legal Officer | $285k 7,342 shares | -46% | |
| 30Weak | TEVA PHARMACEUTICAL INDUSTRIES LTD | Ronit Satchi-Fainaro director | $15k 415 shares | -0% | |
| 40Moderate | TEVA PHARMACEUTICAL INDUSTRIES LTD | Amir Weiss Chief Accounting Officer | $355k 9,445 shares | -47% | |
| 41Moderate | TEVA PHARMACEUTICAL INDUSTRIES LTD | Evan Lippman EVP, Business Development | $680k 18,600 shares | -42% | |
| 30Weak | TEVA PHARMACEUTICAL INDUSTRIES LTD | Tal Zvi Zaks director | $593 17 shares | -0% | |
| 23Weak | TEVA PHARMACEUTICAL INDUSTRIES LTD | Eric A Hughes See "Remarks" | $892k 25,578 shares | -16% | |
| 32Weak | TEVA PHARMACEUTICAL INDUSTRIES LTD | Placid Jover See "Remarks" | $447k 12,827 shares | -65% | |
| 64Notable | TEVA PHARMACEUTICAL INDUSTRIES LTD | Matthew Shields EVP, Global Operations | $322k 9,989 shares | -100% | |
| 62Notable | TEVA PHARMACEUTICAL INDUSTRIES LTD | Eliyahu Sharon Kalif EVP, Chief Financial Officer | $3.6M 106,563 shares | -62% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.